血流动力学
医学
内科学
生物标志物
心脏病学
血流动力学反应
慢性血栓栓塞性肺高压
肺动脉高压
血压
心率
生物化学
化学
作者
Steffen Kriechbaum,Christoph B. Wiedenroth,Karina Peters,Marta A. Barde,Ruth Ajnwojner,J S Wolter,Moritz Haas,Fritz Roller,Stefan Guth,Andreas Rieth,Andreas Rolf,Christian W. Hamm,Eckhard Mayer,Till Keller,Christoph Liebetrau
出处
期刊:Biomarkers
[Informa]
日期:2020-09-22
卷期号:25 (7): 578-586
被引量:21
标识
DOI:10.1080/1354750x.2020.1821776
摘要
Purpose This study examined sST2, GDF-15, and galectin-3 as indicators of disease severity and therapy response in chronic thromboembolic pulmonary hypertension (CTEPH).Methods This study included 57 inoperable CTEPH patients who underwent balloon pulmonary angioplasty and 25 controls without cardiovascular disease. Biomarker levels were examined in relation to advanced hemodynamic impairment [tertile with worst right atrial pressure (RAP) and cardiac index], hemodynamic therapy response [normalized hemodynamics (meanPAP ≤25 mmHg, PVR ≤3 WU and RAP ≤6 mmHg) or a reduction of meanPAP ≥25%; PVR ≥ 35%, RAP ≥25%].Results GDF-15 [820 (556–1315) pg/ml vs. 370 (314–516) pg/ml; p < 0.001] and sST2 [53.7 (45.3–74.1) ng/ml vs. 48.7 (35.5–57.0) ng/ml; p = 0.02] were higher in CTEPH patients than in controls. At baseline, a GDF-15 level ≥1443 pg/ml (AUC 0.88; OR 31.4) and a sST2 level ≥65 ng/ml (AUC 0.80; OR 10.9) were associated with advanced hemodynamic impairment. At follow-up GDF-15 ≤ 958 pg/ml (AUC = 0.74, OR 18) identified patients with optimal hemodynamic therapy response and ≤760 pg/ml (AUC = 0.79, OR 14).Conclusion GDF-15 and sST2 levels are higher in CTEPH and identified patients with advanced hemodynamic impairment. Further, decreased GDF-15 levels at follow-up were associated with hemodynamic therapy response. The diagnostic strength was not superior to NT-proBNP.
科研通智能强力驱动
Strongly Powered by AbleSci AI